Bone turnover following autologous transplantation in multiple myeloma

Clark, Richard E. and Fraser, William D. (2002) Bone turnover following autologous transplantation in multiple myeloma. Leukemia & Lymphoma, 43 (3). pp. 511-516. ISSN 1042-8194

Full text not available from this repository. (Request a copy)


Most patients with multiple myeloma have lytic lesions at multiple sites in the axial skeleton. These lesions commonly give pain and are at risk of pathological fracture, and bony disease is therefore a cause of much morbidity in myeloma. Recent data indicates that the Receptor Activator of NF- κ B ligand (RANKL) and Osteoprotegerin (OPG) may be central to the local pathogenesis of these lytic lesions. Bisphosphonates may ameliorate some of these abnormalities, and clinically these agents improve the skeletal prognosis in myeloma patients. High dose chemotherapy with autologous stem cell rescue is currently under evaluation in the management of myeloma, though little is known of the effect of this therapeutic modality on the skeleton. Studies using biochemical markers of bone turnover suggest that increased osteoclast activity may be present even in apparent plateau phase of myeloma. High dose chemotherapy with autografting may normalise abnormal bone resorption, though the effect may take several weeks to emerge, and may be paralleled by increased osteoblast activity. The findings provide biochemical evidence that autografting may help normalise the abnormal bone turnover characteristic of myeloma.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Musculoskeletal Medicine
Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Depositing User: Rhiannon Harvey
Date Deposited: 07 Jun 2011 15:16
Last Modified: 19 Oct 2023 01:02
DOI: 10.1080/10428190290011985

Actions (login required)

View Item View Item